These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 8044832

  • 1. Reduction in the toxicity of aminopterin--monoclonal-antibody conjugates by leucovorin.
    Rowland AJ, Pietersz GA.
    Cancer Immunol Immunother; 1994 Aug; 39(2):135-9. PubMed ID: 8044832
    [Abstract] [Full Text] [Related]

  • 2. Anti-tumour activity of aminopterin-monoclonal antibody conjugates; in vitro and in vivo comparison with methotrexate-monoclonal antibody conjugates.
    Kanellos J, Pietersz GA, Cunningham Z, McKenzie IF.
    Immunol Cell Biol; 1987 Dec; 65 ( Pt 6)():483-93. PubMed ID: 3502340
    [Abstract] [Full Text] [Related]

  • 3. The comparative effects of IL-1 and TNF on AMN-anti-Ly 2.1 immunoconjugate therapy.
    Krauer KG, Pietersz GA.
    Biotherapy; 1993 Dec; 6(2):139-47. PubMed ID: 8398573
    [Abstract] [Full Text] [Related]

  • 4. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs.
    Rowland AJ, McKenzie IF, Pietersz GA.
    J Drug Target; 1994 Dec; 2(2):113-21. PubMed ID: 8069589
    [Abstract] [Full Text] [Related]

  • 5. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy.
    Russell SM, Krauer KG, McKenzie IF, Pietersz GA.
    Cancer Res; 1990 Sep 15; 50(18):6028-33. PubMed ID: 2393867
    [Abstract] [Full Text] [Related]

  • 6. Intratumour therapy of solid tumours with ricin-antibody conjugates.
    Kanellos J, McKenzie IF, Pietersz GA.
    Immunol Cell Biol; 1989 Apr 15; 67 ( Pt 2)():89-99. PubMed ID: 2786496
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model.
    Smyth MJ, Bogdanovski M, McKenzie IF, Pietersz GA.
    Cancer Res; 1991 Jan 01; 51(1):310-7. PubMed ID: 1988093
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts.
    Krauer KG, McKenzie IF, Pietersz GA.
    Cancer Res; 1992 Jan 01; 52(1):132-7. PubMed ID: 1530766
    [Abstract] [Full Text] [Related]

  • 9. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.
    Rowland AJ, Pietersz GA, McKenzie IF.
    Cancer Immunol Immunother; 1993 Aug 01; 37(3):195-202. PubMed ID: 7687521
    [Abstract] [Full Text] [Related]

  • 10. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates.
    Pietersz GA, Smyth MJ, McKenzie IF.
    Cancer Res; 1988 Feb 15; 48(4):926-31. PubMed ID: 3422182
    [Abstract] [Full Text] [Related]

  • 11. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA, Carroll SF, Snover DC, Carlson GJ, Blazar BR.
    Blood; 1991 Jan 01; 77(1):182-94. PubMed ID: 1984794
    [Abstract] [Full Text] [Related]

  • 12. Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-alpha in mice.
    Pietersz GA, Bogdanovski M, Li W.
    Immunol Cell Biol; 1997 Jun 01; 75(3):253-8. PubMed ID: 9243290
    [Abstract] [Full Text] [Related]

  • 13. In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours.
    Kanellos J, MacKenzie IF, Pietersz GA.
    Immunol Cell Biol; 1988 Jun 01; 66 ( Pt 5-6)():403-15. PubMed ID: 3265693
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of T-2 toxin-conjugated monoclonal antibody to murine thymoma.
    Ohtani K, Murakami H, Shibuya O, Kawamura O, Ohi K, Chiba J, Otokawa M, Ueno Y.
    Jpn J Exp Med; 1990 Apr 01; 60(2):57-65. PubMed ID: 2384978
    [Abstract] [Full Text] [Related]

  • 15. Evidence that an anthracycline-anti-CD8 immunoconjugate, idarubicin-anti-Ly-2.1, prolongs heart allograft survival in mice.
    Mottram PL, Pietersz GA, Smyth MJ, Purcell LJ, Clunie GJ, McKenzie IF.
    Transplantation; 1993 Mar 01; 55(3):484-90. PubMed ID: 8456465
    [Abstract] [Full Text] [Related]

  • 16. Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate.
    Melton RG, Rowland JA, Pietersz GA, Sherwood RF, McKenzie IF.
    Eur J Cancer; 1993 Mar 01; 29A(8):1177-83. PubMed ID: 8518030
    [Abstract] [Full Text] [Related]

  • 17. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
    Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR.
    Cancer Res; 1992 Oct 15; 52(20):5693-700. PubMed ID: 1382845
    [Abstract] [Full Text] [Related]

  • 18. Studies on the reversal of aminopterin toxicity in the rat with citrovorum factor, folacin and related compounds.
    SAUBERLICH HE.
    J Nutr; 1953 May 15; 50(1):101-15. PubMed ID: 13061987
    [No Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
    Biddle WC, Haruta Y, Seon BK, Henderson ES, Sarcione EJ.
    Leuk Res; 1989 May 15; 13(8):699-707. PubMed ID: 2529399
    [Abstract] [Full Text] [Related]

  • 20. The mode of action of methotrexate-monoclonal antibody conjugates.
    Smyth MJ, Pietersz GA, McKenzie IF.
    Immunol Cell Biol; 1987 Apr 15; 65 ( Pt 2)():189-200. PubMed ID: 3610218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.